The latest price target for AstraZeneca (NASDAQ:AZN) was reported by Erste Group on September 11, 2024. The analyst firm set a price target for $0.00 expecting AZN to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AstraZeneca (NASDAQ:AZN) was provided by Erste Group, and AstraZeneca upgraded their buy rating.

The last upgrade for AstraZeneca PLC happened on September 11, 2024 when Erste Group raised their price target to N/A. Erste Group previously had a hold for AstraZeneca PLC.

The last downgrade for AstraZeneca PLC happened on February 8, 2024 when Deutsche Bank changed their price target from N/A to N/A for AstraZeneca PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AstraZeneca, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AstraZeneca was filed on September 11, 2024 so you should expect the next rating to be made available sometime around September 11, 2025.

While ratings are subjective and will change, the latest AstraZeneca (AZN) rating was a upgraded with a price target of $0.00 to $0.00. The current price AstraZeneca (AZN) is trading at is $65.12, which is out of the analyst’s predicted range.